Legislation Aims to Ban Animal Research at Public Universities Legislation referred to as “Queenie’s Law,” was reintroduced in...
Read PostAdvocacy
Championing Bio-Industry Progress
Stay informed on advocacy efforts driving growth and innovation in the bio-industry. This category features updates, initiatives, and insights focused on promoting policies and actions that support our thriving community.
Michigan Senate Passes Controversial 340B Program Bills The Michigan Senate overwhelmingly passed bills, SB 94 and SB 95, that “prohibits...
Read PostNew Bill Aims to Strengthen USPTO-FDA Collaboration A bill titled “The Interagency Patent Coordination and Improvement Act,” or S....
Read PostBipartisan Effort Revives Rare Pediatric Disease Program The bipartisan “Give Kids a Chance Act of 2025”, or H.R. 1262, was...
Read PostDefending Biomedical Innovation Amid NIH Budget Threats MichBio, along with numerous other bio-industry groups, continues to press Congress and...
Read PostMichBio to Visit Capitol Hill and Discuss Biotech/Pharma Issues MichBio is heading back to Capitol Hill on April 1 and 2 as part of the annual...
Read PostMajor Changes at HHS: Workforce Cuts, Reorganization, and New Leadership The Department of Health & Human Services (HHS) announced 10,000 job...
Read PostDiscover MichBio, Michigan's bioscience industry leader. Explore membership benefits, events, advocacy efforts, and the latest news on drug...
Read PostJoin MichBio in advocating for the medtech industry! Discover our initiatives, events, and membership benefits to support innovation in Michigan's...
Read PostStay updated on Michigan's Earned Sick Time Act changes, including new employer requirements and employee rights. Learn how these updates impact...
Read PostDiscover how NIH funding cuts threaten U.S. leadership in life science innovation. MichBio advocates for research sustainability and economic growth.
Read PostStay updated on Michigan's 340B contract pharmacy access legislation. Explore its implications for healthcare costs and transparency in drug pricing.
Read Post